Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cubist Pharmaceuticals has entered a license agreement with AstraZeneca for the development and commercialization of the antibiotic Cubicin in China and certain other countries in Asia, the Middle East and Africa.
Subscribe to our email newsletter
The agreement does not include Japan, which is yet to be partnered.
In exchange for development and commercialization rights, AstraZeneca has agreed to pay Cubist $10.25 million cash upfront. In addition, Cubist will receive payments on reaching regulatory and sales milestones. AstraZeneca will pay Cubist an undisclosed price for the supply of Cubicin vials to be sold in the licensed territory.
“China is a very important growth market for pharmaceuticals, in particular antibiotics such as Cubicin,” said Mike Bonney, president and CEO of Cubist.
Cubicin is currently the only once-daily bactericidal antibiotic approved in the US indicated for the treatment of complicated skin and skin structure infections. Cubicin is also approved in the US as therapy for blood stream infections.